Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2026-03-18 @ 2:18 AM
Study NCT ID:
NCT06000033
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-21
First Post:
2023-08-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
Sponsor:
Qilu Hospital of Shandong University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
RC48HR-/HER2LOW
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None